Jones, Edward G.
Mazaheri, Neda
Maroofian, Reza
Zamani, Mina
Seifi, Tahereh
Sedaghat, Alireza
Shariati, Gholamreza
Jamshidi, Yalda http://orcid.org/0000-0003-0151-6482
Allen, Hugh D.
Wehrens, Xander H. T.
Galehdari, Hamid
Landstrom, Andrew P. http://orcid.org/0000-0002-1878-9631
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01-HL089598, R01-HL091947, R01-HL117641, K08-HL136839, L40-HL129273)
Pediatric and Congenital Electrophysiology Society, McCrae Foundation
Article History
Received: 5 September 2018
Accepted: 24 May 2019
First Online: 21 June 2019
Competing Interests
: XHTW is a founding partner of Elex Biotech, a start-up company that developed drug molecules that target ryanodine receptors for the treatment of cardiac arrhythmia disorders. All other offers declare no potential conflict of interest.